Trials
Search / Trial NCT06439706

HPV Self-sampling for Underscreened Latinas

Launched by FOX CHASE CANCER CENTER · May 28, 2024

Trial Information

Current as of February 12, 2025

Completed

Keywords

ClinConnect Summary

The study team will recruit a sample of underscreened Latinas (n=100) who will be randomly assigned to either the educational intervention (n=50) or a control condition (n=50). Feasibility will be measured through study enrollment and intervention completion (defined as the proportion of women who self-collect a sample). Acceptability of intervention materials and self-sampling procedures will be measured using self-report surveys at follow-up assessments.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Self-reported Hispanic/Latina ethnicity
  • Assigned female sex at birth
  • Age 30-65, consistent with guidelines for HPV DNA testing for cervical cancer screening
  • Speak and read English or Spanish
  • Computer or other device with internet connection
  • Overdue for cervical cancer screening (e.g., no cytology-based screening within the past 3 years; no hrHPV testing either alone or in combination with cytology in the past 5 years).
  • Exclusion Criteria:
  • Prior diagnosis of cervical cancer or abnormality (e.g., dysplasia)
  • Had a hysterectomy/removal of the cervix
  • Compromised immune system (e.g., known HIV)
  • Women who self-report that they are pregnant or are within three months after a pregnancy

Trial Officials

Carolyn Fang, PhD

Principal Investigator

Fox Chase Cancer Center

About Fox Chase Cancer Center

Fox Chase Cancer Center is a leading academic research institution dedicated to advancing cancer treatment and prevention through innovative clinical trials and cutting-edge research. As a National Cancer Institute-designated Comprehensive Cancer Center, it combines a multidisciplinary approach with a commitment to patient-centered care, fostering collaboration among experts in oncology, surgery, radiation therapy, and supportive care. Fox Chase is renowned for its pioneering contributions to cancer research, translating discoveries into effective therapies and improving patient outcomes, while also prioritizing education and community outreach to enhance public awareness of cancer prevention and treatment options.

Locations

Philadelphia, Pennsylvania, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0